drugset / Trial / NCT04239586

Switching From Insulin to Sulfonylurea in Diabetes Associated With Variants in MODY Genes

NCT04239586

Phase 4 Unknown 30 enrolled Haukeland University Hospital
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to switch from insulin to oral sulfonylurea in patients with apparent type 1 diabetes or maturity onset diabetes in the young that are insulin treated. The molecular cause will be DNA variants in the HNF1A, HNF4A, or HNF1B genes that are of unknown significance (VUS, class 3) or known to be pathogenic (class 4 and 5).

Timeline

Start
2017-04-18
Primary completion
2022-04
Completion
2022-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Glimepiride Small molecule Oral
Subject Glipizide Small molecule Oral
Subject Glyburide Small molecule Oral